Skip to content

Transpara

by Screenpoint Medical B.V. 2 variants

510(k) K181704

Active European Union and United States

CE MDR CE MDD 510(k)

Valid until

No date given

CE: no date in EUDAMED. FDA: not time-limited

FDA recalls

None found

in data synced 6 Oct 2026

Documents

None linked in EUDAMED

A group certificate may exist

Trust

Unverified

Source EUDAMED, FDA 510(k), synced 6 Oct 2026.

Regulatory status

as of registry sync 6 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA 510(k)SESE 510(k) Substantially Equivalent · Traditional NumberK181704 Date21 Nov 2018ClearedStatusActive
European UnionCE/MDD EUDAMED Number— Date—StatusActive
European UnionCE/MDR EUDAMED Number— Date—StatusActive

Official records

From the FDA record

Received by the FDA
27 Jun 2018
FDA decision
21 Nov 2018 (Substantially Equivalent)
FDA review time
147 days from receipt to decision
Public document
510(k) summary on file with the FDA

From the FDA 510(k) record K181704 (openFDA), as read on 6 Oct 2026. Quoted as published, gaps included; nothing on this list is generated.

Across registries

2 registries list this device

  • FDA 510(k) K181704 decided 21 Nov 2018 Active
  • EUDAMED Active· +1 more in the status table

Coverage

2 jurisdictions

United States of AmericaSwedenFinlandLatviaEstoniaDenmarkLithuaniaIrelandNetherlandsGermanyPolandFranceBelgiumLuxembourgCzech RepublicSlovakiaAustriaHungaryRomaniaSloveniaBulgariaPortugalSpainItalyCroatiaGreeceMaltaCyprus
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered
  • European Union CE/MDD, CE/MDR Active
  • United States FDA 510(k) Active

Specification

EUDAMED · 510(k)

510(k) Number
FDA product code
QDQ
Device class
Class II
Regulation
21 CFR Part 892.2090
Advisory committee
Radiology
FDA decision
SESE Substantially Equivalent

Overview

AI-generated summary, 18 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

Transpara is a Class II radiological computer-assisted detection and diagnosis software designed to identify lesions suspicious for cancer in imaging studies. It leverages advanced algorithms to enhance radiologist workflow by flagging potential abnormalities in mammograms, CT scans, and other radiographic modalities for further evaluation.

The software is supplied as a digital tool integrated into radiology workstations and requires no physical storage or sterilisation. It operates in MRI-safe environments and is intended for single-use per imaging session, though the underlying software license may allow repeated use across multiple studies. Authorised under FDA 510(k) clearance, MDD, and MDR compliance, it adheres to regulatory standards for diagnostic imaging software in radiology settings.

Devices cleared under K181704

1 device · FDA GUDID

Devices that FDA's GUDID lists as cleared or approved under this submission number. One submission usually covers a whole product family, so the sizes and models are listed here once.

Devices cleared under K181704
UDI-DISize and differences
Transpara 1.3.y
Screenpoint Medical B.V.
1.3.y08719326450100 —On the market

Similar devices

Other devices filed under FDA product code QDQ (Radiological Computer Assisted Detection/Diagnosis Software For Lesions Suspicious For Cancer).

Other devices from Screenpoint Medical B.V.

See all devices from Screenpoint Medical B.V. →